II
SRPT icon

IFM Investors’s Sarepta Therapeutics SRPT Stock Holding History

IFM Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,656
Closed -$645K – 610
2021
Q1 		$645K Buy
8,656
+1,774
+26% +$164K 0.02% 589
2020
Q4 		$1.17M Buy
6,882
+931
+16% +$138K 0.04% 462
2020
Q3 		$836K Buy
5,951
+526
+10% +$79.9K 0.04% 453
2020
Q2 		$870K Sell
5,425
-1,894
-26% -$258K 0.04% 384
2020
Q1 		$721K Buy
7,319
+151
+2% +$17.3K 0.03% 462
2019
Q4 		$925K Sell
7,168
-414
-5% -$41.8K 0.03% 491
2019
Q3 		$571K Buy
+7,582
New +$895K 0.02% 561

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

IFM Investors's SRPT Position: Q2 2021 in Review

IFM Investors sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 8,656 shares — an estimated $645K sold.

IFM Investors first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $1.17M in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • IFM Investors reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • IFM Investors sold 8,656 Sarepta Therapeutics shares in Q2 2021, an estimated $645K.
  • IFM Investors first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
  • IFM Investors's Sarepta Therapeutics position peaked at $1.17M in Q4 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on IFM Investors's 13F filing for Q2 2021, filed 16 Jul 2021.